1,882 product recalls found in this category. Browse through all safety alerts and stay informed.
High Activity Category
This category has a significant number of recalls. Please check regularly for updates.
Teva-affiliated Clonidine Transdermal System recalls 113,943 cartons after CGMP deviations. Unapproved raw material prompts recall. Stop use immediately and contact Teva or a healthcare provider for guidance.
Teva Pharmaceuticals recalled 124,054 cartons of Clonidine Transdermal System due to CGMP deviations from an unapproved raw material. The recall affects products sold in the United States. Consumers should stop using the product immediately and consult a healthcare provider for guidance.
Amneal Pharmaceuticals is recalling 29,542 bottles of TRAMADOL HYDROCHLORIDE tablets distributed nationwide in the United States. The recall cites a failed impurity specification for N-nitroso-desmethyl-tramadol (NDSRI) at the 24‑month stability interval. Consumers and healthcare providers should stop using the product immediately and contact Amneal for guidance.
Teva Pharmaceuticals recalled 21,930 cartons of Octreotide Acetate for Injectable Suspension distributed nationwide in the United States. The recall stems from lack of assurance of sterility identified during an FDA inspection at the contract manufacturer. Healthcare providers and patients should stop using this product immediately and contact Teva or a physician for guidance.
Straumann USA LLC recalls 7 Custom Abutment AS Ti for Straumann RC. The recall follows a material mix-up during manufacturing. A TAN material bar was incorrectly identified as Titanium Bar Ti Gr4 D, causing RC Titanium abutments to be made with TAN material. Stop using the device and contact Straumann for instructions immediately.
Xanax XR extended-release alprazolam recall issued March 17, 2026 remains active. Viatris Specialty LLC distributes the drug nationwide in the United States. The issue is failed dissolution specifications. Patients and healthcare providers should stop using the product immediately and follow the recall instructions for guidance.
Teva Pharmaceuticals USA recalled 19,869 cartons of Octreotide Acetate for Injectable Suspension nationwide in the United States after FDA inspection flagged lack of assurance of sterility at the contract manufacturer. The FDA cited quality system deficiencies at Pharmathen International S.A. in Greece. Healthcare providers and patients should stop using the product immediately and contact Teva or
Straumann USA recalled 13 Custom Abutment Ti RC units distributed worldwide, including the United States and Canada. A TAN material was misidentified as Titanium Ti Gr4 D during manufacturing, causing RC Titanium abutments to be made from TAN material. Clinics and patients should stop using the devices immediately and follow recall instructions from Straumann USA or their healthcare providers.
Chiesi USA recalled 7,235 Curosurf vials distributed nationwide to hospitals and clinics. The recall cites a lack of assurance of sterility. Healthcare providers should stop using the product immediately and contact Chiesi USA for guidance.
Teva Pharmaceuticals recalled 1,897 cartons of Octreotide Acetate for Injectable Suspension distributed nationwide in the USA after an FDA inspection flagged sterility concerns. The recall is due to lack of assurance of sterility from the contract manufacturer. Consumers and healthcare providers should stop using the product immediately and contact Teva for guidance.
Meclizine Hydrochloride Tablets distributed nationwide by Amerisource Health Services LLC are being recalled. The two affected NDCs are 60687-775-65 and 60687-775-11. The recall is due to failed tablet specifications. Stop using the product and contact a healthcare provider for guidance immediately.
Cipla USA Inc. recalls 54,583 Lanreotide acetate injections nationwide after FDA flagged sterility assurance concerns at a contract manufacturer. The recall covers a box containing one pre-filled syringe and one safety needle. Healthcare providers and patients should stop using the product immediately and follow the company’s guidance for disposal and refunds.
Cipla USA, Inc. recalls lanreotide acetate 120 mg/0.5 mL pre-filled syringes distributed nationwide due to lack of assurance of sterility after FDA observations at the contract manufacturer. Health care providers and patients should stop use immediately and contact Cipla or their clinician for guidance.
Stryker Sustainability Solutions recalled 56,740 color cuff tourniquet cuffs due to potential detachment from the bladder. The recall affects 18" and 24" cuffs across multiple U.S. states. Patients and healthcare providers should stop using these devices immediately and follow manufacturer instructions.
Brahms GmbH recalled 5,254 units of the PlGF Plus KRYPTOR in vitro diagnostic test worldwide after reports of QC values out of range at QC Level 1. The issue may cause falsely elevated sFlt-1/PlGF ratios and higher risk classifications for preeclampsia progression. Stop using the device immediately and follow manufacturer recall instructions.
Fresenius Kabi USA, LLC recalls 5% Dextrose Injection, USP 12.5 g per 250 mL in FreeFlex bags due to lack of sterility assurance. The recall covers units distributed nationwide including Alaska and Puerto Rico. Healthcare providers and patients should stop use and consult a healthcare professional.
Fresenius Kabi USA, LLC recalled 5% Dextrose Injection, USP, 50 mL in a 100 mL freeflex bag, distributed nationwide including Alaska and Puerto Rico. The recall cites lack of assurance of sterility. Consumers and healthcare providers should stop using this product immediately and contact Fresenius Kabi for guidance.
BD Becton, Dickinson and Company and Fresenius Kabi USA recall 0.9% Sodium Chloride Injection, USP, 250 mL in a single-dose bag nationwide, including Alaska and Puerto Rico. The recall cites lack of assurance of sterility. Healthcare providers and patients should stop using the product immediately and follow guidance from Fresenius Kabi or their provider.
Fresenius Kabi USA recalled saline injections distributed nationwide, including Alaska and Puerto Rico. The action covers multiple batch numbers with sterility concerns. Healthcare providers and patients should stop using the product immediately and follow official guidance for replacement options.
Fresenius Kabi USA recalled 0.9% Sodium Chloride Injection nationwide, including Alaska and Puerto Rico. The recall is due to lack of assurance of sterility. Healthcare providers should stop using the product immediately and contact Fresenius Kabi for guidance.